LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

Search

Celldex Therapeutics Inc

Abrir

SetorSaúde

31.7 1.93

Visão Geral

Variação de preço das ações

24h

Atual

Mín

31.12

Máximo

32.31

Indicadores-chave

By Trading Economics

Rendimento

-14M

-81M

Vendas

75K

75K

EPS

-1.22

Margem de lucro

-108,422.667

Funcionários

198

EBITDA

-7.8M

-81M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+72.84% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

501M

2.1B

Abertura anterior

29.77

Fecho anterior

31.7

Sentimento de Notícias

By Acuity

100%

0%

333 / 350 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Celldex Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

24 de mar. de 2026, 18:58 UTC

Grandes Movimentos do Mercado

MDA Space Shares Drop After NASA Shifts Focus to Moon's Surface and Away From Space Station

24 de mar. de 2026, 23:48 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

24 de mar. de 2026, 23:48 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for U.S.-Iran Talks -- Market Talk

24 de mar. de 2026, 23:33 UTC

Conversa de Mercado
Notícias Principais

Gold Rises, Boosted by Dollar Weakness -- Market Talk

24 de mar. de 2026, 23:16 UTC

Conversa de Mercado

Venezuelan Opposition Leader Says Oil Output Could Reach 5 Million B/D -- Market Talk

24 de mar. de 2026, 22:40 UTC

Ganhos

Shanghai Fosun Pharmaceutical: Results Supported by Higher Rev From Innovative Drugs, Overseas Business >2196.HK

24 de mar. de 2026, 22:40 UTC

Ganhos

Shanghai Fosun Pharmaceutical 2025 Net CNY3.37B Vs. Net CNY2.77B >2196.HK

24 de mar. de 2026, 22:40 UTC

Ganhos

Shanghai Fosun Pharmaceutical 2025 Rev CNY41.50B Vs. CNY40.91B >2196.HK

24 de mar. de 2026, 21:44 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

24 de mar. de 2026, 21:44 UTC

Conversa de Mercado

Sandfire's New Bull Excited by Kalkaroo Copper Deposit -- Market Talk

24 de mar. de 2026, 20:59 UTC

Ganhos

Medtronic PLC Cuts FY26 View To Adj EPS $5.50-Adj EPS $5.54 >MDT

24 de mar. de 2026, 20:58 UTC

Notícias Principais

Israel Hits Russian-Iranian Weapons Smuggling Route in the Caspian Sea -- WSJ

24 de mar. de 2026, 20:50 UTC

Conversa de Mercado
Notícias Principais

Energy & Utilities Roundup: Market Talk

24 de mar. de 2026, 20:50 UTC

Conversa de Mercado
Notícias Principais

Basic Materials Roundup: Market Talk

24 de mar. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

24 de mar. de 2026, 20:25 UTC

Ganhos

This Palantir-Linked Drone Stock Was Flying Under the Radar -- Until Now -- Barrons.com

24 de mar. de 2026, 20:15 UTC

Conversa de Mercado
Notícias Principais

Global Commodities Roundup: Market Talk

24 de mar. de 2026, 20:10 UTC

Conversa de Mercado

Canada Mortgage Arrears Linked to Labor Market Performance -- Market Talk

24 de mar. de 2026, 20:10 UTC

Ganhos

Worthington Enterprises 3Q Sales $378.7M >WOR

24 de mar. de 2026, 20:10 UTC

Ganhos

Worthington Enterprises 3Q Adj EPS 98c >WOR

24 de mar. de 2026, 20:10 UTC

Ganhos

Worthington Enterprises 3Q EPS 92c >WOR

24 de mar. de 2026, 19:25 UTC

Conversa de Mercado
Notícias Principais

Canada Needs Roughly 100 Days to Meet IEA's Oil-Stock Release -- Market Talk

24 de mar. de 2026, 19:06 UTC

Conversa de Mercado
Notícias Principais

Oil Futures Regain Ground As Strikes Continue in Middle East -- Market Talk

24 de mar. de 2026, 18:51 UTC

Conversa de Mercado
Notícias Principais

U.S. Natural Gas Settles Higher As Oil Futures Gain -- Market Talk

24 de mar. de 2026, 18:40 UTC

Conversa de Mercado
Notícias Principais

Global Forex and Fixed Income Roundup: Market Talk

24 de mar. de 2026, 18:40 UTC

Conversa de Mercado
Notícias Principais

Mideast Conflict to Hobble But Not Derail Canadian Economy -- Market Talk

24 de mar. de 2026, 18:34 UTC

Notícias Principais

Oil Production in the Middle East Will Take Months to Come Back, CEO says. Why $100 Oil Could Be Here to Stay. -- Barrons.com

24 de mar. de 2026, 18:27 UTC

Conversa de Mercado

Inflation Pickup Could Keep Bank of Mexico on Hold -- Market Talk

24 de mar. de 2026, 18:21 UTC

Conversa de Mercado
Notícias Principais

Silver Snaps 9-Session Losing Streak -- Market Talk

24 de mar. de 2026, 18:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Gilead to Buy Ouro Medicines for $2.2 Billion. Why the Deal Is Key to Future Stock Gains. -- Barrons.com

Comparação entre Pares

Variação de preço

Celldex Therapeutics Inc Previsão

Preço-alvo

By TipRanks

72.84% parte superior

Previsão para 12 meses

Média 53.91 USD  72.84%

Máximo 90 USD

Mínimo 24 USD

Com base em 12 analistas de Wall Street que oferecem metas de preço de 12 meses para Celldex Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

12 ratings

10

Comprar

1

Manter

1

Vender

Pontuação Técnica

By Trading Central

18.91 / 20.63Suporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
help-icon Live chat